Main study purpose:~To assess the safety and tolerability of IMM0306 in combination with lenalidomide to determine the maximum tolerated dose (MTD) (if available) and the recommended Phase 2 dose (RP2D).~Secondary study purpose~To assess the antitumor efficacy of IMM0306 in combination with lenalidomide.~To assess the immunogenicity of IMM0306 in combination with lenalidomide.~To evaluate the pharmacokinetic (PK) profile of IMM0306 in combination with lenalidomide.~Exploratory study purpose:~Explore the correlation between exposure to IMM0306 and efficacy and safety (data permitting).~Explore the correlation of biomarkers with safety.
The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.